PUNE,
India, April 26, 2024 /PRNewswire/ -- The report
titled "Anti-Mullerian Hormone Test Market by
Product (POC Testing, Self-check Kits), End-User (Commercial Labs,
Research & development), Distribution, Use - Global Forecast
2024-2030" is now available on 360iResearch.com's
offering, presents an analysis indicating that the market projected
to grow from a size of $274.26
million in 2023 to reach $586.48
million by 2030, at a CAGR of 11.46% over the forecast
period.
"Global Need for AMH Testing Grows as
Reproductive Health Awareness Rises"
Anti-mullerian hormone (AMH) tests are critical in assessing a
woman's remaining egg count, potential fertility, and the health of
her ovaries. These tests serve vital functions in diagnosing
conditions such as polycystic ovary syndrome (PCOS) and primary
ovarian insufficiency, as well as in guiding treatment in various
reproductive procedures, including in vitro fertilization (IVF).
Challenges include high costs and a lack of widespread awareness,
particularly in regions with limited resources. The global market
for AMH tests is expanding, driven by increased awareness of
reproductive health issues, an upward trend in the age of
first-time mothers, and technological advancements that enhance the
accessibility and effectiveness of these diagnostic tests. Regions
such as Asia-Pacific are
witnessing significant growth due to increased health expenditures,
a shift toward preventive healthcare, advanced healthcare
infrastructures, and a proactive approach to fertility issues
supporting mature markets such as the Americas and Western Europe. Eastern Europe, the Middle East, and Africa are developing at varying rates, fueled
by improvements in healthcare systems and initiatives aimed at
bolstering women's health services.
Download Sample Report
@ https://www.360iresearch.com/library/intelligence/anti-mullerian-hormone-test
"The Crucial Role of Anti-Müllerian Hormone
Testing in Addressing the Global Rise of Polycystic Ovary
Syndrome"
Polycystic ovary syndrome (PCOS) is one of the prevalent
endocrine diseases among women of reproductive age, affecting
approximately 8% to 13% worldwide, according to the World Health
Organization (WHO). This condition often leads to various symptoms
due to hormonal imbalance, including menstrual irregularities and
infertility, with many cases remaining undiagnosed. A key tool in
identifying PCOS is the Anti-Müllerian hormone (AMH) test, which
measures the levels of AMH produced by ovarian follicles. Elevated
AMH levels can indicate PCOS, as women with the disorder typically
exhibit a higher count of antral follicles. The increasing
awareness of fertility issues and the escalating occurrences of
PCOS highlight the growing need for AMH testing solutions.
Healthcare providers can better manage and potentially mitigate the
long-term impacts of PCOS, emphasizing the need for early
interventions and promoting healthier lifestyles among affected
individuals by facilitating early diagnosis through AMH tests.
"Home and Clinical Testing Is On The Rise
of Point-of-Care AMH Tests"
Point-of-care (POC) testing for anti-Mullerian hormone (AMH)
revolutionizes the approach to fertility evaluations by providing
rapid results in non-traditional settings such as clinics and
homes. These user-friendly tests are designed with simplicity in
mind, requiring little to no prior technical expertise, and
dramatically reduce the waiting period for results. This immediacy
is critical in fertility treatments and ovarian function
assessments, where timely decision-making is essential. For
individuals assessing their fertility independently, self-check AMH
kits offer the privacy and convenience of testing at home without
the need for immediate professional involvement. This can be
particularly valuable for those residing in remote areas or with
restricted access to specialized healthcare services. Overall, POC
testing empowers individuals and healthcare providers alike by
streamlining fertility and ovarian reserve evaluations, blending
convenience with accuracy and speed.
Request Analyst Support
@ https://www.360iresearch.com/library/intelligence/anti-mullerian-hormone-test
"Beckman
Coulter, Inc. by Danaher Corporation at the Forefront of
Anti-Mullerian Hormone Test Market with a Strong 13.44% Market
Share"
The key players in the Anti-Mullerian Hormone Test Market
include Bio-Rad Laboratories, Inc., Beckman
Coulter, Inc. by Danaher Corporation, bioMérieux S.A.,
Thermo Fisher Scientific Inc., Siemens Healthineers AG, and others.
These prominent players focus on strategies such as expansions,
acquisitions, joint ventures, and developing new products to
strengthen their market positions.
"Introducing ThinkMi: Revolutionizing
Market Intelligence with AI-Powered Insights for the Anti-Mullerian
Hormone Test Market"
We proudly unveil ThinkMi, a cutting-edge AI product designed to
transform how businesses interact with the Anti-Mullerian Hormone
Test Market. ThinkMi stands out as your premier market intelligence
partner, delivering unparalleled insights with the power of
artificial intelligence. Whether deciphering market trends or
offering actionable intelligence, ThinkMi is engineered to provide
precise, relevant answers to your most critical business questions.
This revolutionary tool is more than just an information source;
it's a strategic asset that empowers your decision-making with
up-to-the-minute data, ensuring you stay ahead in the fiercely
competitive Anti-Mullerian Hormone Test Market. Embrace the future
of market analysis with ThinkMi, where informed decisions lead to
remarkable growth.
Ask Question to ThinkMi
@ https://app.360iresearch.com/library/intelligence/anti-mullerian-hormone-test
"Dive into the Anti-Mullerian Hormone Test
Market Landscape: Explore 195 Pages of Insights, 368 Tables, and 24
Figures"
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Anti-Mullerian Hormone Test Market, by Product
- Anti-Mullerian Hormone Test Market, by End-User
- Anti-Mullerian Hormone Test Market, by Distribution
- Anti-Mullerian Hormone Test Market, by Use
- Americas Anti-Mullerian Hormone Test Market
- Asia-Pacific Anti-Mullerian Hormone Test Market
- Europe, Middle East & Africa Anti-Mullerian
Hormone Test Market
- Competitive Landscape
- Competitive Portfolio
Inquire Before Buying
@ https://www.360iresearch.com/library/intelligence/anti-mullerian-hormone-test
Related Reports:
- Hormone Replacement Therapy Market - Global Forecast
2024-2030
- Human Growth Hormone Market - Global Forecast 2024-2030
- Synthetic Hormones Market - Global Forecast 2024-2030
About 360iResearch
Founded in 2017, 360iResearch is a market research and business
consulting company headquartered in India, with clients and focus markets spanning
the globe.
We are a dynamic, nimble company that believes in carving
ambitious, purposeful goals and achieving them with the backing of
our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes
to market intelligence and volatility. Our market intelligence is
diligent, real-time and tailored to your needs, and arms you with
all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500,
and leading consulting and research companies and academic
institutions that rely on our expertise in compiling data in niche
markets. Our meta-insights are intelligent, impactful and infinite,
and translate into actionable data that support your quest for
enhanced profitability, tapping into niche markets, and exploring
new revenue opportunities.
Contact 360iResearch
Mr. Ketan Rohom
360iResearch Private Limited,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
Email: sales@360iresearch.com
USA: +1-530-264-8485
India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on
LinkedIn, Twitter, and Facebook.
Logo:
https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/anti-mullerian-hormone-test-market-projected-to-reach-586-48-million-by-2030---exclusive-report-by-360iresearch-302126074.html
SOURCE 360iResearch